{"article_title": "CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market", "article_keywords": ["real", "consumers", "cms", "rule", "savings", "cost", "cripple", "fledgling", "undermines", "market"], "article_url": "http://www.forbes.com/sites/gracemarieturner/2015/10/08/cms-rule-undermines-real-cost-savings-for-consumers-could-cripple-fledgling-u-s-biosimilar-market/", "article_text": "", "article_metadata": {"prerender-status-code": "{{meta.code}}", "author": "Grace-Marie Turner", "og": {"site_name": "Forbes", "description": "The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry.", "title": "CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market", "url": "http://www.forbes.com/sites/gracemarieturner/2015/10/08/cms-rule-undermines-real-cost-savings-for-consumers-could-cripple-fledgling-u-s-biosimilar-market/", "image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "updated_time": "2015-10-08T11:31:05-04:00", "type": "article"}, "twitter": {"description": "The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry.", "creator": "@gracemarietweet", "image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "title": "CMS Rule Undermines Real Cost Savings For Consumers & Could Cripple Fledgling U.S. Biosimilar Market", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Healthcare  Fiscal,OpEd,Healthcare &amp; Fiscal,Op/Ed", "article": {"publisher": "https://www.facebook.com/forbes", "author": "http://www.facebook.com/GalenInstitute", "section_url": "http://www.forbes.com/opinion", "section": "Opinion", "modified": "2015-10-08", "published": "2015-10-08", "id": "blogAndPostId/blog/post/1939-1672"}, "news_keywords": "Healthcare  Fiscal,OpEd,Healthcare &amp; Fiscal,Op/Ed", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "description": "The Obama administration is proposing a Medicare payment rule that would have the effect of clamping price controls on biosimilar drugs, extending destructive pricing policies to a potentially vibrant 21st century life sciences industry."}, "_id": "\"57477af46914bd0286fdb93d\"", "article_summary": ""}